The Psilocybin News Report – If you see psilocybin all over the headlines, you’re right!

Yes, psilocybin is in every headline now and that’s exciting!

Psilocybin, better known as magic mushrooms, is clearly all the rage these days.

From consuming the raw real deal to precisely dosed capsules, people are reaping the benefits of magic mushrooms left and right. You’re not wrong: this compound in mushrooms is nothing short of miraculous when it comes to treating a variety of ailments that affect us both mentally and physically. But since it’s still fairly new and less studied compared to traditional drugs, there will always be some kind of backlash.

That being said, here’s some of the biggest news about psilocybin:

Global organization begins work to try and replan psilocybin in UN drug law

On January 11th, the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI) launched its campaign for global reform of medicinal mushrooms. They note that the notoriously old 1971 UN Convention on Psychotropic Substances needs serious updating, as it was originally put in place to keep people away from harmful drugs. They work in partnership with the Beckley Foundation, Mind Medicine Australia, MAPS, Osmond Foundation, Open Foundation and Nierika AC.

However, we now have more data that psilocybin is therapeutic and therefore requires a change in its category.

“In most countries, the legal control of psilocybin stems from its Schedule I status under the 1971 Convention on Psychotropic Substances,” they said in a press release. “Planned for dangerous drugs that pose a particularly serious public health risk and have little to no therapeutic value, Schedule I drugs are subject to severe restrictions on their scientific and medical use. Schedule I’s licensing, custody, security, manufacturing, quantity, and import/export restrictions result in a level of regulatory control and oversight that is dramatically more onerous than for the Convention’s other three schedules. As a result, researchers looking to study psilocybin face numerous regulatory hurdles that can significantly increase the cost, complexity and duration of research, and negatively impact ethical approvals, funding and collaboration.”

“Given today’s scientific understanding of psilocybin’s high potential therapeutic value and low risk of dependence, a change in its Schedule I drug status is long overdue.”

Med School focuses on psychedelic therapy for PTSD, anxiety and depression

Researchers at Dell Medical School at the University of Texas at Austin have just launched the Center for Psychedelic Research and Therapy. It is the first of its kind in the state, with a focus on clinical research aimed at determining the potential of psilocybin, as well as other psychedelics including ibogaine, ayahuasca and MDMA, to treat PTSD, anxiety and major depression when used concomitantly with Treatment by a trained professional.

“This research will bring further scientific rigor and expertise to the study of psychedelic therapy,” said Charles B. Nemeroff, co-director of the center and chair and professor of Dell Med’s Division of Psychiatry and Behavioral Sciences these drugs show great promise when combined with clinical support, and this work has the potential to transform the way we treat conditions like depression and PTSD and to identify synergies between these and other established therapies to improve long-term Achieving results benefits those seeking treatment.”

They begin with a focus on military veterans suffering from PTSD, adults living with depression or prolonged grief, and those struggling with childhood trauma.

Low doses of psilocybin have no harmful long or short term effects

In early January 2022, researchers released the results of a study showing that there were no harmful long- or short-term effects when 10 or 25 mg doses of psilocybin were administered to groups of healthy individuals. The researchers, from the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, were the first step they took to demonstrate the compound’s safety in treating a range of conditions, including treatment-resistant PTSD. They add that in controlled situations, psilocybin should be taken alongside talk therapy.

“This rigorous study is an important first demonstration that psilocybin co-administration can be further explored,” said lead author James Rucker, PhD. “As we consider how psilocybin therapy (if approved) may be administered in the future, it is important to demonstrate the feasibility and safety of administering to more than one person at a time so we can consider how to scale this up can treatment.”

Throughout, they found that the participants showed no results of long- or short-term effects as a result of psilocybin ingestion.

Israeli startup working on pharmaceutical grade psychedelic extracts for mental health

Israeli pharma startup PsyRx believes that naturally-derived psychedelics may hold the key to treating mental illness, and they’re working on it now.

“The world desperately needs a new way to treat mental health issues, and at PsyRx we believe psychedelics are a big part of the solution,” said co-founder and CEO Itay Hecht. The company uses an agromedical bioreactor it developed at the Hebrew University Faculty of Agriculture to produce psychedelic botanical extracts of psilocybin from mushrooms and ibogaine from the root bark of the iboga shrub.

These natural ingredients show promise in treating addiction, depression, PTSD, and anxiety, especially when compared to dangerous and addictive SSRI drugs that have been the norm for decades. “SSRIs have some very bad side effects on libido and appetite, and patients often stop using them. We believe that adding a microdose of ibogaine counteracts these effects and makes a better drug,” explains Hecht, adding that microdosing psychedelics does not cause hallucinations.

“We will soon begin small animal trials to verify safety and efficacy. Hopefully we can start human trials in a year,” he told ISRAEEL21C.

MORE ABOUT PSILOCYBIN, READ THIS…

MUSHROOMS HELP ALCOHOLICS STOP BURNING IN NEW STUDY!

OR..

HOW PSILOCYBIN HELPS TREAT DEPRESSION READ THIS!